An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.
NCT00628927, Completed, University of Cincinnati; results first posted 2013-08-30
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers. | ClinicalTrials.gov |
| NCT number | NCT00628927 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 217 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Cincinnati | ClinicalTrials.gov |
| Conditions | Stimulant Dependence | ClinicalTrials.gov |
| First posted | 2008-03-05 | ClinicalTrials.gov |
| Last updated | 2015-12-30 | ClinicalTrials.gov |
| Results first posted | 2013-08-30 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Stroop Color-word Task | Single study visit | The primary objective of this study was to replicate the finding that performance on the Stroop color-word interference task is predictive of treatment completion in participants with cocaine use disorders (Streeter et al., 2007) and to extend this finding to participants with methamphetamine use disorders. In the Stroop, the participant is required to name the color of the ink in which a word is printed while inhibiting the overlearned response of reading the word (e.g., the word ''red'' might be printed in blue ink). The number of errors were subtracted from the time required (RT; Reaction Time) for each of the 3 trials, yielding three summary scores. The derived interference score is obtained by subtracting the RT for the first trial from the RT for the third trial. | ClinicalTrials.gov |
| Secondary | Barrett Impulsiveness Scale Version 11 (BIS-11) | Single study visit | The BIS-11 consists of 30 self-report items, with responses in a four-point Likert-type scale (0 - 3)ranging from "Rarely/Never" to "Almost Always/Always" and comprises three domains: Attentional impulsiveness (AI), Motor impulsiveness (MI), and Non-planning impulsiveness (NP); these three domains are summed to yield a total score; higher scores reflect greater impulsivity. The total score was utilized as the BIS-11 predictor measure (possible score range 0 - 90). | ClinicalTrials.gov |
| Secondary | Tail Length From the Comet Assay for Oxidative Damage | Single study visit | The test for oxidative damage was derived from a blood sample which was analyzed for tail length from the comet assay; higher scores reflect greater oxidative damage. | ClinicalTrials.gov |
Outcomes 3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | Stroop Color-word Task | Single study visit | seconds | MEAN | ClinicalTrials.gov | |
| SECONDARY | Barrett Impulsiveness Scale Version 11 (BIS-11) | Single study visit | units on a scale | MEAN | ClinicalTrials.gov | |
| SECONDARY | Tail Length From the Comet Assay for Oxidative Damage | Single study visit | µm | MEAN | ClinicalTrials.gov |
Results by group 7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| Stroop Color-word Task | Stimulant Dependent Completers | 55.4 | Standard Deviation 22.9 | seconds | ClinicalTrials.gov | |
| Stroop Color-word Task | Stimulant Dependent Treatment Non-Completers | 50.5 | Standard Deviation 21.0 | seconds | ClinicalTrials.gov | |
| Barrett Impulsiveness Scale Version 11 (BIS-11) | Stimulant Dependent Completers | 66.7 | Standard Deviation 9.3 | units on a scale | ClinicalTrials.gov | |
| Barrett Impulsiveness Scale Version 11 (BIS-11) | Stimulant Dependent Treatment Non-Completers | 69.4 | Standard Deviation 7.5 | units on a scale | ClinicalTrials.gov | |
| Tail Length From the Comet Assay for Oxidative Damage | Stimulant Dependent Completers | 17.3 | Standard Deviation 10.1 | µm | ClinicalTrials.gov | |
| Tail Length From the Comet Assay for Oxidative Damage | Stimulant Dependent Treatment Non-Completers | 15.6 | Standard Deviation 8.5 | µm | ClinicalTrials.gov | |
| Tail Length From the Comet Assay for Oxidative Damage | Normal Controls | 16.5 | Standard Deviation 7.2 | µm | ClinicalTrials.gov |
Participant flow 6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | Simulant Dependent Participants | 183 | ClinicalTrials.gov | |
| Overall Study | STARTED | Normal Control Participants | 30 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Simulant Dependent Participants | 175 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Normal Control Participants | 30 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Simulant Dependent Participants | 8 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Normal Control Participants | 0 | ClinicalTrials.gov |
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 6
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | Simulant Dependent Participants | ClinicalTrials.gov | ||
| Total, all-cause mortality | Normal Control Participants | ClinicalTrials.gov | ||
| Total, other adverse events | Simulant Dependent Participants | 0 | 175 | ClinicalTrials.gov |
| Total, other adverse events | Normal Control Participants | 0 | 30 | ClinicalTrials.gov |
| Total, serious adverse events | Simulant Dependent Participants | 0 | 175 | ClinicalTrials.gov |
| Total, serious adverse events | Normal Control Participants | 0 | 30 | ClinicalTrials.gov |
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| U10DA013732 | Clinical Trials Network, Ohio Valley Node U10DA013732 | WINHUSEN, T JOHN | UNIVERSITY OF CINCINNATI | NATIONAL INSTITUTE ON DRUG ABUSE | 2000 to 2015 | NIH RePORTER |
Trial comparisons 1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Simulant Dependent Participants vs Normal Control Participants: serious adverse events | Trial comparisons |
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)